PL80303B1 - - Google Patents

Download PDF

Info

Publication number: PL80303B1
Authority: PL; Poland
Prior art keywords: poly; vaccine; influenza; molecular weight; virus
Prior art date: 1968-09-19

Application number

PL1969135883A

Other languages

English (en)

Polish (pl)

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1968-09-19

Filing date

1969-09-18

Publication date

1975-08-30

1969-09-18 Application filed filed Critical

1975-08-30 Publication of PL80303B1 publication Critical patent/PL80303B1/pl

Links

108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 claims description 36
239000000427 antigen Substances 0.000 claims description 35
102000036639 antigens Human genes 0.000 claims description 35
108091007433 antigens Proteins 0.000 claims description 35
239000002671 adjuvant Substances 0.000 claims description 28
108091033319 polynucleotide Proteins 0.000 claims description 27
239000002157 polynucleotide Substances 0.000 claims description 27
102000040430 polynucleotide Human genes 0.000 claims description 27
238000000034 method Methods 0.000 claims description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000012752 auxiliary agent Substances 0.000 claims description 21
229920001519 homopolymer Polymers 0.000 claims description 21
241000712461 unidentified influenza virus Species 0.000 claims description 18
229960003971 influenza vaccine Drugs 0.000 claims description 16
239000000839 emulsion Substances 0.000 claims description 15
238000002360 preparation method Methods 0.000 claims description 14
239000000546 pharmaceutical excipient Substances 0.000 claims description 12
239000003921 oil Substances 0.000 claims description 11
235000019198 oils Nutrition 0.000 claims description 11
229920000642 polymer Polymers 0.000 claims description 11
239000000463 material Substances 0.000 claims description 8
239000003795 chemical substances by application Substances 0.000 claims description 7
230000008569 process Effects 0.000 claims description 5
229920005603 alternating copolymer Polymers 0.000 claims description 4
235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
239000008158 vegetable oil Substances 0.000 claims description 4
RUIBNPJLTRFMOD-SPIULWCRSA-N [(2R,3S,4R,5R)-5-(6-amino-6-methyl-8H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound P(=O)(O)(O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1CN=C2C(N)(N=CN=C12)C)O)O RUIBNPJLTRFMOD-SPIULWCRSA-N 0.000 claims description 2
QMTUFQCZIXGIGA-BOVONTJDSA-N C[N+]1=CN([C@]2([C@H](O)[C@H](O)[C@@H](CO)O2)C(=O)[O-])C=2N=CN=C(C1=2)O Chemical compound C[N+]1=CN([C@]2([C@H](O)[C@H](O)[C@@H](CO)O2)C(=O)[O-])C=2N=CN=C(C1=2)O QMTUFQCZIXGIGA-BOVONTJDSA-N 0.000 claims 1
229960005486 vaccine Drugs 0.000 description 44
241000700605 Viruses Species 0.000 description 21
230000000694 effects Effects 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
230000000890 antigenic effect Effects 0.000 description 12
239000002253 acid Substances 0.000 description 10
241000700198 Cavia Species 0.000 description 9
230000005875 antibody response Effects 0.000 description 9
238000002255 vaccination Methods 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
206010022000 influenza Diseases 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
239000000126 substance Substances 0.000 description 7
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
229940124873 Influenza virus vaccine Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000002245 particle Substances 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
235000019483 Peanut oil Nutrition 0.000 description 4
101710137302 Surface antigen S Proteins 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000013566 allergen Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
229920001577 copolymer Polymers 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000000312 peanut oil Substances 0.000 description 4
241000282412 Homo Species 0.000 description 3
239000013011 aqueous formulation Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 3
239000002480 mineral oil Substances 0.000 description 3
235000010446 mineral oil Nutrition 0.000 description 3
230000000405 serological effect Effects 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000007815 allergy Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000000428 dust Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
244000005700 microbiome Species 0.000 description 2
229920002477 rna polymer Polymers 0.000 description 2
238000012360 testing method Methods 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229930024421 Adenine Natural products 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000712083 Canine morbillivirus Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
241000193155 Clostridium botulinum Species 0.000 description 1
241000193468 Clostridium perfringens Species 0.000 description 1
241000193449 Clostridium tetani Species 0.000 description 1
241000694440 Colpidium aqueous Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010017711 Gangrene Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
241000713196 Influenza B virus Species 0.000 description 1
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
241000589902 Leptospira Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
208000005647 Mumps Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
208000010359 Newcastle Disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000606856 Pasteurella multocida Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000831652 Salinivibrio sharmensis Species 0.000 description 1
241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
241000577483 Salmonella enterica subsp. enterica serovar Paratyphi B Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000011651 chromium Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
238000000586 desensitisation Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000002964 excitative effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000446 fuel Substances 0.000 description 1
JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000037798 influenza B Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
208000010805 mumps infectious disease Diseases 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000019488 nut oil Nutrition 0.000 description 1
239000010466 nut oil Substances 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
201000006509 pleuropneumonia Diseases 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
239000002574 poison Substances 0.000 description 1
-1 pollen Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229940038578 respiratory vaccine Drugs 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000002435 venom Substances 0.000 description 1
231100000611 venom Toxicity 0.000 description 1
210000001048 venom Anatomy 0.000 description 1
239000002023 wood Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL1969135883A 1968-09-19 1969-09-18 PL80303B1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US76100468A	1968-09-19	1968-09-19

Publications (1)

Publication Number	Publication Date
PL80303B1 true PL80303B1 (de)	1975-08-30

Family

ID=25060824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL1969135883A PL80303B1 (de)	1968-09-19	1969-09-18

Country Status (18)

Country	Link
JP (1)	JPS502009B1 (de)
AT (1)	AT296500B (de)
BE (1)	BE739046A (de)
BR (1)	BR6912481D0 (de)
CA (1)	CA918072A (de)
CS (1)	CS160110B2 (de)
DE (1)	DE1946319A1 (de)
DK (1)	DK128503B (de)
ES (1)	ES371557A1 (de)
FI (1)	FI46863C (de)
FR (1)	FR2018431B1 (de)
GB (1)	GB1234718A (de)
IE (1)	IE33578B1 (de)
IL (1)	IL32962A (de)
NL (1)	NL167324C (de)
PL (1)	PL80303B1 (de)
SE (1)	SE364987B (de)
ZA (1)	ZA695759B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8301996A (nl) *	1983-06-06	1985-01-02	Duphar Int Res	Werkwijze ter bereiding van geadjuveerde levende vaccins en aldus verkregen geadjuveerde levende vaccins.
ATE292980T1 (de)	1996-10-11	2005-04-15	Univ California	Immunostimulierende oligonucleotidekonjugate

1969
- 1969-08-12 ZA ZA695759A patent/ZA695759B/xx unknown
- 1969-09-01 NL NL6913336.A patent/NL167324C/xx not_active IP Right Cessation
- 1969-09-08 IL IL32962A patent/IL32962A/xx unknown
- 1969-09-09 IE IE1263/69A patent/IE33578B1/xx unknown
- 1969-09-09 FI FI692588A patent/FI46863C/fi active
- 1969-09-12 DE DE19691946319 patent/DE1946319A1/de active Pending
- 1969-09-15 GB GB45333/69A patent/GB1234718A/en not_active Expired
- 1969-09-15 ES ES371557A patent/ES371557A1/es not_active Expired
- 1969-09-15 SE SE12648/69A patent/SE364987B/xx unknown
- 1969-09-16 BR BR212481/69A patent/BR6912481D0/pt unknown
- 1969-09-16 CA CA062152A patent/CA918072A/en not_active Expired
- 1969-09-17 CS CS6319A patent/CS160110B2/cs unknown
- 1969-09-18 PL PL1969135883A patent/PL80303B1/pl unknown
- 1969-09-18 FR FR696931843A patent/FR2018431B1/fr not_active Expired
- 1969-09-18 BE BE739046D patent/BE739046A/xx unknown
- 1969-09-18 DK DK497969AA patent/DK128503B/da unknown
- 1969-09-19 AT AT892669A patent/AT296500B/de not_active IP Right Cessation
- 1969-09-19 JP JP44074057A patent/JPS502009B1/ja active Pending

Also Published As

Publication number	Publication date
NL167324B (nl)	1981-07-16
SU441711A3 (ru)	1974-08-30
BR6912481D0 (pt)	1973-02-08
FR2018431B1 (de)	1973-06-08
FI46863C (fi)	1973-07-10
ES371557A1 (es)	1972-03-16
JPS502009B1 (de)	1975-01-23
IE33578B1 (en)	1974-08-21
DE1946319A1 (de)	1970-03-26
CS160110B2 (de)	1975-02-28
GB1234718A (en)	1971-06-09
IL32962A0 (en)	1969-11-30
CA918072A (en)	1973-01-02
IL32962A (en)	1973-01-30
SE364987B (de)	1974-03-11
FI46863B (de)	1973-04-02
AT296500B (de)	1972-02-10
FR2018431A1 (de)	1970-05-29
IE33578L (en)	1970-03-19
BE739046A (de)	1970-03-18
NL6913336A (de)	1970-03-23
ZA695759B (en)	1971-03-31
DK128503B (da)	1974-05-13
NL167324C (nl)	1981-12-16

Publication	Publication Date	Title
US3906092A (en)	1975-09-16	Stimulation of antibody response
US5679356A (en)	1997-10-21	Use of GM-CSF as a vaccine adjuvant
DE60023300T2 (de)	2006-07-06	Verwendung von cpg als adjuvans für hivimpstoff
EP4332225A1 (de)	2024-03-06	Verwendung von künstlich synthetisiertem cpg-einzelstrangigem deoxyoligonukleotid in impfstoffen
JP2001526688A (ja)	2001-12-18	オリゴヌクレオチドアジュバント
JP2023506440A (ja)	2023-02-16	免疫刺激性組成物及びその用途
JP2018510874A (ja)	2018-04-19	アジュバント組成物及び関連する方法
CA2327389C (en)	2011-06-14	Dna vaccine for horses containing as at least one adjuvant, polymers of acrylic or methacrylic acid, or copolymers of maleic anhydride and ethylene
KR20080016592A (ko)	2008-02-21	폴리이노신산-폴리시티딜산-기초 보조제
Hilleman	1970	Double-stranded RNAs (poly I: C) in the prevention of viral infections
DE69929432T2 (de)	2006-09-28	Erhöhung der immunantworten bei genetischer immunisierung durch verwendung eines chemokins
Gazdar et al.	1972	Interferon inducers: enhancement of viral oncogenesis in mice and rats
Sommer et al.	2006	Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy
CA2435568A1 (en)	2002-08-01	Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment
PL80303B1 (de)	1975-08-30
EP1957101A2 (de)	2008-08-20	Dsrna als influenza-virus-impfstoffadjuvantien oder immunostimulatoren
CN111420043A (zh)	2020-07-17	一种治疗乙型肝炎的药物组合物、其制备方法及用途
CN101559225B (zh)	2012-07-11	脑膜炎球菌疫苗
Worthington et al.	1971	Effectiveness of an interferon stimulator in immunosuppressed mice
JP3072489B2 (ja)	2000-07-31	免疫刺激効果を誘出する製薬組成物
CN118001385A (zh)	2024-05-10	流感疫苗组合物及其制备方法和应用
CN109701011B (zh)	2022-04-05	疫苗复合佐剂系统及其在抗原中的应用
CN113967252B (zh)	2024-03-26	一种禽用免疫增强剂、含有免疫增强剂的疫苗组合物及其应用
Billiau et al.	1971	Adjuvant activity of polyacetal carboxylate for antibody induction in mice and guinea pigs
CN106163554B (zh)	2021-09-07	一种包含pika佐剂的狂犬病组合物